- Regeneron Pharmaceuticals, Inc. stock price today and history
Regeneron Pharmaceuticals, Inc. (REGN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Regeneron Pharmaceuticals, Inc. stock price
Regeneron Pharmaceuticals, Inc. latest news:
Regeneron's stock rallies after profit and sales rise above expectations
Shares of Regeneron Pharmaceuticals Inc. rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased to $388.3 million, or $3.32 a share, from $264.8 million, or $2.27 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $3.99, beating the FactSet consensus of $3.82. Revenue rose to $1.50 billion from $1.22 billion, above the FactSet consensus of $1.45 billion, as net product sales, Sanofi collaboration revenue and Bayer collaboration revenue all beat expectations. Sales of its lead retinal therapy Eylea rose 12% to $953 million, beating the FactSet consensus of $935 million. The stock has fallen 14% over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has slipped 0.1% and the S&P 500 has gained 4.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
Oct 16 (Reuters) - Regeneron Pharmaceuticals Inc
and Sanofi SA said on Monday their drug to treat
inflammation in the esophagus, mainly caused by food allergies,
met the main goal of a mid-stage study.
Federated, Carnival, Alphabet climb; Regeneron skids
Federated National Holding, Carnival and Alphabet rise while Regeneron Pharmaceuticals trades lower
BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma
Regeneron Pharmaceuticals Inc(REGN). * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Co, Sanofi announced pivotal phase 3 liberty asthma quest study of met its two primary endpoints.
Biotech stocks rally, ETF on track for third straight daily gain
Biotechnology stocks rallied on Wednesday, with one of the biggest exchange-traded funds dedicated to the sector on track for its third straight daily advance. The iShares Nasdaq Biotechnology ETF gained 1.3%, bringing its week-to-date rise to 3.6%. Among the biggest gainers in the sector, Gilead Sciences Inc. popped 5.6%, bringing its gain over the past three months to 23.7%. The stock is on track for its largest percentage gain since November, as well as its highest close since September 2016. Separately, Incyte Corp. added 4.5% while BioMarin Pharmaceutical Inc. advanced 4.8%. Biogen Inc. gained 2.4% while Regeneron Pharmaceuticals Inc. was up 2%. On the downside within the pharmaceutical sector, U.S.-listed shares of Novartis AG were down 1%. The company's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Regulus Therapeutics Inc.RGLS
Reliv'' International, Inc.RELV
Remark Media, Inc.MARK
Remy International, Inc.REMY
Renewable Energy Group, Inc.REGI